	US 12,440,549 B2
	Polyvalent immunogenicity composition for human papillomavirus
Liangzhi Xie, Beijing (CN); Chunxia Luo, Beijing (CN); Wei Zhang, Beijing (CN); Xiaoyan Suo, Beijing (CN); Lin Pang, Beijing (CN); and Ping Hu, Beijing (CN)
Assigned to SinocellTech Ltd., Beijing (CN)
Filed by SinoCellTech Ltd., Beijing (CN)
Filed on Jan. 19, 2022, as Appl. No. 17/579,459.
Application 17/579,459 is a continuation of application No. PCT/CN2020/102601, filed on Jul. 17, 2020.
Claims priority of application No. 201910657255.8 (CN), filed on Jul. 19, 2019.
Prior Publication US 2022/0370590 A1, Nov. 24, 2022
Int. Cl. A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/12 (2013.01) [A61K 39/39 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/55505 (2013.01)]

7 Claims

1. A multivalent HPV immunogenic composition for preventing HPV-related diseases or infections, wherein the composition comprises:

HPV virus-like particles assembled from the chimeric L1 protein of HPV Types 6, 11, 16, 18, 31, 35, 39, 45, 51, 52, 56, 58 and L1 protein of HPV Types 33 and 59;

wherein the chimeric L1 protein of HPV Type 6 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 1; and (b) a C-terminal fragment which is SEQ ID No: 2;

wherein the chimeric L1 protein of HPV Type 11 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 14; and (b) a C-terminal fragment which is SEQ ID No: 15;

wherein the chimeric L1 protein of HPV Type 16 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 27; and (b) a C-terminal fragment which is SEQ ID No: 28;

wherein the chimeric L1 protein of HPV Type 18 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 40; and (b) a C-terminal fragment which is SEQ ID No: 41;

wherein the chimeric L1 protein of HPV Type 31 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 53; and (b) a C-terminal fragment which is SEQ ID No: 54;

wherein the chimeric L1 protein of HPV Type 35 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 69; and (b) a C-terminal fragment which is SEQ ID No: 70;

wherein the chimeric L1 protein of HPV Type 39 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 82; and (b) a C-terminal fragment which is SEQ ID No: 83;

wherein the chimeric L1 protein of HPV Type 45 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 95; and (b) a C-terminal fragment which is SEQ ID No: 96;

wherein the chimeric L1 protein of HPV Type 51 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 108; and (b) a C-terminal fragment which is SEQ ID No: 109;

wherein the chimeric L1 protein of HPV Type 52 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 121; and (b) a C-terminal fragment which is SEQ ID No: 122;

wherein the chimeric L1 protein of HPV Type 56 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 134 and (b) a C-terminal fragment which is SEQ ID No: 135;

wherein the chimeric L1 protein of HPV Type 58 comprises, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment which is SEQ ID No: 147; and (b) a C-terminal fragment which is SEQ ID No: 148;

wherein the HPV Type 33 L1 protein is SEQ ID No: 66 and

wherein the HPV Type 59 L1 protein is SEQ ID No: 160.